PD-(L)1 monotherapy can be used as a second-line treatment for metastatic non-small-cell lung cancer (NSCLC) with PD-L1 expression. However, many patients do not respond, and reliable biomarkers are lacking.
A Angeles合作论文数1L. Daniello合作论文数1J. Kuon合作论文数1Lena Gaissmaier合作论文数1Florian Janke合作论文数1H. Schindler合作论文数1M. Kirchner合作论文数1
Rajiv Shah合作论文数Dept Thorac Oncol, Heidelberg Univ Hosp1
Daniel Kazdal合作论文数Institut für Pathologie, Universitätsklinikum Heidelberg Heidelberg1Bozorgmehr Farastuk合作论文数1Christopoulos Petros合作论文数1
Florian Eichhorn合作论文数Department of Thoracic Surgery, Heidelberg University1Albrecht Stenzinger合作论文数Institute of Pathology, University Hospital1Martin Schneider合作论文数1
Holger Sultmann合作论文数Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany1
